VGX 3100

Drug Profile

VGX 3100

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; VGX-3100

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • Clinical Phase Unknown Head and neck cancer

Most Recent Events

  • 24 Apr 2017 Phase-II clinical trials in Vulvar intraepithelial neoplasia (IM)
  • 15 Mar 2017 Inovio Pharmaceuticals plans a phase II trial for Vulvar intraepithelial neoplasia
  • 13 Feb 2017 VGX 3100 licensed to ApolloBio in China, Hong Kong, Macao, Taiwan for the treatment of Human papillomavirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top